Polyclonal Antibody to TRAIL-R1 (CT)

Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including TNF and Fas ligand (CD95L) of the TNF family through their death domain containing receptors, TNF-R1 and Fas (CD95). A novel death domain containing receptor was identified and designated DR4 (for death receptor 4) [1]. The ligand for this novel death receptor has been identified and termed TRAIL [2,3], which is a member in the TNF family. DR4 is also called TRAIL receptor-1 (TRAIL-R1) [4]. DR4 is expressed in most human tissues including spleen, thymus, small intestine and peripheral blood leukocytes. Like TNF-R1, Fas and DR3, DR4 mediates apoptosis and NF-κB activation in many tissues and cells.